You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

BAUSCH AND LOMB Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for BAUSCH AND LOMB
International Patents:476
US Patents:49
Tradenames:76
Ingredients:58
NDAs:83

Drugs and US Patents for BAUSCH AND LOMB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb ALAWAY ketotifen fumarate SOLUTION/DROPS;OPHTHALMIC 021996-001 Dec 1, 2006 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb OPCON-A naphazoline hydrochloride; pheniramine maleate SOLUTION/DROPS;OPHTHALMIC 020065-001 Jun 8, 1994 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb GENTAMICIN SULFATE gentamicin sulfate SOLUTION/DROPS;OPHTHALMIC 064048-001 May 11, 1994 AT RX No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BAUSCH AND LOMB

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc TIMOPTIC timolol maleate SOLUTION/DROPS;OPHTHALMIC 018086-002 Approved Prior to Jan 1, 1982 3,655,663 ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 7,928,122 ⤷  Try for Free
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 6,699,492 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09
➤ Subscribe Ophthalmic Solution 0.07% ➤ Subscribe 2013-07-26
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2012-10-19

Supplementary Protection Certificates for BAUSCH AND LOMB Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0206283 98C0041 Belgium ⤷  Try for Free PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
0694547 2002/028 Ireland ⤷  Try for Free PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0809498 10C0038 France ⤷  Try for Free PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

BAUSCH AND LOMB Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: BAUSCH AND LOMB – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Bausch and Lomb stands out as a prominent player, particularly in the eye care sector. Let's dive into a comprehensive analysis of their market position, strengths, and strategic insights that have shaped their competitive landscape.

The Eye Care Giant: An Overview

Bausch and Lomb, a subsidiary of Bausch Health Companies, has been a pioneer in eye health for over 165 years. Their journey from a small optical goods shop to a global eye health company is nothing short of remarkable. But how does this legacy translate into their current market position?

A Vision for Success

Bausch and Lomb's success isn't just about longevity; it's about innovation and adaptability. Their diverse product portfolio spans across vision care, surgical, and pharmaceutical segments, giving them a unique edge in the market.

"Bausch + Lomb's fully integrated eye-health business helps it maintain an edge over competition"[10]

This integrated approach allows them to cater to a wide range of eye health needs, from contact lenses to complex surgical equipment.

Market Position: A Clear View

Global Footprint

Bausch and Lomb's market position is bolstered by its strong global presence. Operating in over 100 countries, the company has successfully established itself as a worldwide leader in eye health[6]. This extensive reach not only diversifies their revenue streams but also insulates them from market fluctuations in any single region.

Revenue Streams

Let's break down their revenue streams to get a clearer picture:

  1. Vision Care: In Q4 2023, this segment generated $662 million, showing a 6% growth from the previous year[3].
  2. Surgical: This division brought in $204 million, with a 9% year-over-year increase[3].
  3. Pharmaceuticals: The star performer, this segment saw a whopping 67% growth, reaching $307 million[3].

These figures paint a picture of a company with robust and diverse revenue sources, a key factor in maintaining a strong market position.

Strengths: The Cornerstones of Success

1. Innovative Product Portfolio

Bausch and Lomb's strength lies in its diverse and innovative product range. From Lumify eye drops to advanced surgical equipment, they cover the entire spectrum of eye care needs.

2. Brand Recognition

With over a century and a half in the business, Bausch and Lomb has built unparalleled brand recognition. This legacy translates into customer trust and loyalty, a priceless asset in the healthcare industry.

3. Research and Development

The company's commitment to R&D is evident in its pipeline of 225 products[10]. This focus on innovation ensures they stay ahead of the curve in a rapidly evolving industry.

4. Strategic Acquisitions

Bausch and Lomb's strategic acquisitions, like the recent purchase of the Blink eye drop brand from Johnson & Johnson, demonstrate their commitment to expanding their portfolio and market share[5].

Strategic Insights: Navigating the Future

Embracing Digital Health

In an increasingly digital world, Bausch and Lomb is not just keeping up; they're leading the charge. Their exploration of smart lens technology and partnerships with tech firms open up new avenues for growth and innovation[2].

Focus on Emerging Markets

The company's strategic focus on emerging markets, particularly in Asia-Pacific and Latin America, positions them to capitalize on the growing demand for eye care products in these regions[2].

Sustainability and Corporate Responsibility

In an era where consumers are increasingly conscious of corporate ethics, Bausch and Lomb's emphasis on sustainability and social responsibility is not just admirable—it's strategic[4].

Challenges on the Horizon

While Bausch and Lomb's position is strong, they're not without challenges:

1. Debt Management

The company's high debt levels, with a debt-to-equity ratio of 2.1, pose a significant financial challenge[2].

2. Supply Chain Issues

Recent supply chain disruptions have impacted their contact lens business, highlighting the need for more robust supply chain management[5].

3. Intense Competition

The eye care market is highly competitive, with giants like Johnson & Johnson and Alcon vying for market share[4].

Future Outlook: A Vision for Growth

Despite these challenges, Bausch and Lomb's future looks promising. Analysts project a revenue growth of approximately 6% per year through 2025, with EBITDA expected to reach around $1.2 billion by 2025[2].

Strategies for Market Domination

To maintain and improve their market position, Bausch and Lomb could consider:

  1. Doubling down on digital health innovations
  2. Expanding their presence in emerging markets
  3. Focusing on debt reduction to improve financial flexibility
  4. Investing in supply chain resilience
  5. Continuing to innovate in high-growth areas like dry eye treatments and premium IOLs

Key Takeaways

  • Bausch and Lomb's integrated approach to eye health gives them a unique market position.
  • Their global presence and diverse product portfolio are key strengths.
  • The company's focus on R&D and strategic acquisitions positions them well for future growth.
  • Challenges include debt management and supply chain issues.
  • Future success will likely hinge on digital health innovations and expansion in emerging markets.

FAQs

  1. What is Bausch and Lomb's main competitive advantage? Their main advantage is their fully integrated eye-health business, covering vision care, surgical, and pharmaceutical segments.

  2. How is Bausch and Lomb addressing the digital health trend? They're exploring partnerships with tech firms for smart lens technology and investing in digital health innovations.

  3. What are the main challenges facing Bausch and Lomb? Key challenges include high debt levels, supply chain disruptions, and intense market competition.

  4. How is Bausch and Lomb positioned in emerging markets? They're strategically focusing on expanding in emerging markets, particularly in Asia-Pacific and Latin America.

  5. What's the projected growth rate for Bausch and Lomb? Analysts project a revenue growth of approximately 6% per year through 2025.

Sources cited: [1] https://www.investopedia.com/bausch-lomb-stock-jumps-after-better-than-expected-earnings-guidance-8598083 [2] https://dcfmodeling.com/blogs/health/blco-financial-health [3] https://ir.bausch.com/sites/bauschhealth-ir/files/2024-02/4q23-bausch-lomb-earnings-presentation.pdf [4] https://canvasbusinessmodel.com/blogs/brief-history/bausch-health-brief-history [5] https://www.morningstar.com/stocks/bausch-lomb-earnings-gains-eye-care-pharma-record-strong-sales-offset-supply-issues [6] https://www.marketing91.com/swot-analysis-bausch-lomb/ [10] https://www.swotandpestle.com/bausch-health/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.